💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

🔍 What makes reserve antibiotics crucial in the fight against antimicrobial resistance?

The recent assessment of Meropenem/Vaborbactam by the G-BA highlights its vital role as a reserve antibiotic for severe gram-negative infections, ensuring effective treatment options when others fail. With tight regulations and stewardship in place, its designation underscores the importance of preserving these powerful tools in modern medicine.

Dive into the article to explore the implications for healthcare, economics, and patient safety.

#SyenzaNews #HealthcareInnovation #HealthEconomics

🤖 Are you ready for the future of surgery?

The recent approval of 11 robotic surgery systems by NICE could improve patient care in the NHS, leading to faster recoveries and minimal invasiveness. With a focus on real-world evidence, this transformative step aims to improve health outcomes while addressing access and equity concerns.

Explore how this innovative approach will shape the landscape of surgical procedures in the coming years!

#SyenzaNews #HealthcareInnovation #MedicalDevices #MarketAccess